AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing ...

Reports

2

Domains carrying it

2

First reported

3 September 2026

Latest report

3 September 2026

◆ Sectors

◆ Where

United States

◆ Timeline

1. 3 September 2026AbbVie claims Phase 3 win for multiple myeloma drug etentamigendpoints.news
2. 3 September 2026AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing ...prnewswire.com

◆ Connected developments

Situations Wire finds semantically close to this one. Proximity, not cause.

• European Commission Approves Teclistamab Plus Daratumumab for R/R Myeloma2 reports · 2 domains · 24 August 2026
• U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ...12 reports · 12 domains · 17 August 2026
• FDA Grants Accelerated Approval to Iberdomide Combination for Relapsed or Refractory ...3 reports · 3 domains · 13 August 2026
• Orum Therapeutics Receives FDA Clearance For IND Of ORM-1153 In Hematologic Malignancies3 reports · 3 domains · 24 August 2026
• FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer59 reports · 51 domains · 5 September 2026
• US FDA approves Replimune's skin cancer drug15 reports · 14 domains · 10 August 2026

◆ Share

◆ Evidence

2 reports · 2 domains

• AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing ...prnewswire.com · 3 September 2026
• AbbVie claims Phase 3 win for multiple myeloma drug etentamigendpoints.news · 3 September 2026